MET and cancer: Although targeting protein–protein interactions using a fragment-based approach unquestionably remains a major challenge, the data reported in the present study demonstrate that a major cancer target such as the HGF/SF-MET interface is amenable to this approach and provide both the building block for a small molecule MET antagonist and a roadmap for developing the MB605 compound into a full therapeutic.